The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Immunological and biological changes during ipilimumab (Ipi) treatment and their correlation with clinical response and survival.
Ester Simeone
Honoraria - Bristol-Myers Squibb
Giusy Gentilcore
No relevant relationships to disclose
Anna Romano
No relevant relationships to disclose
Antonio Daponte
No relevant relationships to disclose
Corrado Caraco
No relevant relationships to disclose
Antonio M Grimaldi
No relevant relationships to disclose
Marcello Curvietto
No relevant relationships to disclose
Assunta Esposito
No relevant relationships to disclose
Paola Queirolo
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Roche/Genentech
Nicola Mozzillo
No relevant relationships to disclose
Paolo Antonio Ascierto
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Roche/Genentech
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Roche/Genentech